Project Hercules Gets Stronger

With Phase I results cleared, Phase II trials now in company's sights

LAWRENCE, MA, USA, October 31, 2017 /EINPresswire.com/ -- Today Rubix LS announces that the initial study results of the Phase I trials for Project Hercules has now been accepted by the FDA to move towards Phase II trials. Project Hercules, the flagship product for Rubix LS, is an amalgamation of merging a physical bio-absorbable implantable device with macro-protein compound fibrous nano-matrix tissue to spurn regeneration from tissue and bone cavitation.

Compared to traditional surgical osteogenesis techniques, Project Hercules has yielded a heralding 98% patient yield in the regeneration of bone cavitation stemmed from per-trochanteric & intertrochanteric hip fractures. With the current osteogenic procedures needing plates, screws, nails and accessories; Project Hercules has proven to mitigate the need for multi-assembly procedures and any adverse re-insertions. Under patient interaction, Project Hercules has decreased time the time for normal human factor function by 110 days.

“We’re absolutely amazed how far Project Hercules has transitioned to a patient interface by way of a Department of Defense Innovation Fund. To know that the impact that this combination device can make, for future patients so that we can move toward a world where everyone will walk normally is astounding,” said Reginald Swift, Founder & CEO of Rubix LS. “Our humble beginnings and vision will help to permeate the vision we’ve been looking for”

Stacy Arrazcaeta
Rubix LS
978-655-6770
email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.
© 1995-2017 IPD Group, Inc. All Right Reserved.